1. Home
  2. APC vs CGEM Comparison

APC vs CGEM Comparison

Compare APC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

APC

ARKO Petroleum Corp. Class A Common Stock

N/A

Current Price

$20.68

Market Cap

920.0M

Sector

Energy

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$13.77

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APC
CGEM
Founded
2025
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
920.0M
904.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
APC
CGEM
Price
$20.68
$13.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$21.75
$30.13
AVG Volume (30 Days)
141.5K
900.4K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
10.99%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.47
N/A
Revenue Next Year
$4.20
$5.20
P/E Ratio
$25.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.08
$5.68
52 Week High
$21.72
$16.74

Technical Indicators

Market Signals
Indicator
APC
CGEM
Relative Strength Index (RSI) 61.44 42.75
Support Level $17.43 $12.41
Resistance Level $21.72 $16.21
Average True Range (ATR) 0.71 0.94
MACD 0.07 -0.16
Stochastic Oscillator 64.98 11.57

Price Performance

Historical Comparison
APC
CGEM

About APC ARKO Petroleum Corp. Class A Common Stock

Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: